New hope for Drug-Resistant TB: experimental combo trial launches
NCT ID NCT07170800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called JDB0131, combined with other TB medications, in 60 people with rifampin-resistant tuberculosis. Participants will receive one of two doses of JDB0131 or a standard drug (delamanid) for 8 weeks. The goal is to see which combination clears the bacteria from sputum faster and more safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JDB0131 benzenesulfonate tablets (a new drug for tuberculosis) combined with other standard TB drugs
- What this could lead to
- If successful, this could provide a new, effective treatment option for people with drug-resistant tuberculosis, potentially shortening treatment time and improving cure rates.
- What could go wrong
- This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The new drug may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Chest Hospital, Capital Medical University
RECRUITINGBeijing, China
-
Changsha Central Hospital
RECRUITINGChangsha, Hunan, China
-
Huashan Hospital Fudan University
NOT_YET_RECRUITINGShanghai, China
-
Public Health Clinical Center of Chengdu
RECRUITINGChengdu, Sichuan, China
-
Shandong Public Health Clinical Center
RECRUITINGJinan, Shandong, China
-
The Second Hospital of Nanjing
RECRUITINGNanjing, Jiangsu, China
-
Wuhan Pulmonary Hospital
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune profiling unlock the hidden stages of tuberculosis?
- Could inhaled TB drugs curb the spread of Drug-Resistant tuberculosis?
- Can new tests predict who will develop active TB?
- Could a 3-Month TB cocktail replace the standard 6-Month regimen?
- Could a simple blood test ensure the right TB dose for kids?
- Community-Driven TB screening aims to reach vulnerable immigrants